Mariner
TCRX icon

Mariner’s TScan Therapeutics TCRX Stock Holding History

Mariner’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,031
Closed -$29.2K – 3799
2025
Q3 		$29.2K Sell
16,031
-1,023
-6% -$1.81K ﹤0.01% 3488
2025
Q2 		$24.7K Buy
17,054
+2,474
+17% +$3.57K ﹤0.01% 3404
2025
Q1 		$20.1K Buy
+14,580
New +$31.5K ﹤0.01% 3380

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Mariner's TCRX Position: Q4 2025 in Review

Mariner sold out of TScan Therapeutics (TCRX) in Q4 2025, closing a stake of 16,031 shares — an estimated $29.2K sold.

Mariner first reported a position in TCRX in Q1 2025 and held it in 3 quarters. The position peaked at $29.2K in Q3 2025. 61 funds tracked by Wall St. Rank hold TCRX as of Q4 2025.

  • Mariner reported no remaining TScan Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Mariner sold 16,031 TScan Therapeutics shares in Q4 2025, an estimated $29.2K.
  • Mariner first reported a position in TScan Therapeutics in Q1 2025 and held it in 3 quarters.
  • Mariner's TScan Therapeutics position peaked at $29.2K in Q3 2025.
  • 61 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2025.

Based on Mariner's 13F filing for Q4 2025, filed 13 Feb 2026.